Millions of individuals globally are affected by chronic respiratory diseases such as asthma and COPD. The number of individuals suffering from allergies involving the respiratory tract is also rising at an alarming rate.
Charles River has a wide range of capabilities to support your respiratory research.
Global Facilities, Expert Staff
With more than 40 inhalation toxicology dosing suites globally, we offer the full range of preclinical study designs:
acute to carcinogenicity
- neonatal and juvenile
MucilAir™ Human Airway Toxicity Test
MucilAir™ (Epithelix) is an in vitro airway respiratory model with morphology and functions mirroring the tracheobronchial epithelium. It has potential applications in inhalation toxicity testing and pharmaceutical lead development, where it may be used to identify potential airway toxicants and facilitate in vivo dose range finding. Learn more.
Two New Robust Respiratory Models Available to Evaluate COPD or Asthma
Charles River has a number of respiratory system models, including the recently validated rodent models for evaluating the potential efficacy of novel anti-inflammatory agents targeting COPD or asthma conditions. Learn more.
Additional respiratory model:
To inquire about our integrated respiratory research services, please contact us at 1.877.CRIVER.1 or firstname.lastname@example.org.
To access exclusive respiratory-related content, including the items listed below, log in to The Source℠. If you are not a member of The Source℠, click here to register.